InvestSMART

CSL Limited (ASX: CSL) - Announcements

Current share price for CSL : $190.150 3.25 (1.74%)+

ASX company news and announcements for CSL Limited (CSL) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All CSL Limited (CSL) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than CSL Limited (CSL), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for CSL Limited (CSL)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$91,389 Half Yearly Report and Accounts 16 Feb 2011 8:29AM $37.020 $190.440 risen by 414.42%
$91,389 Chairman`s Address to Shareholders 13 Oct 2010 10:13AM $32.270 $190.440 risen by 490.15%
$91,389 Announcement of buy-back - Appendix 3C 18 Aug 2010 8:46AM $31.900 $190.440 risen by 496.99%
$91,389 Full Year Results, Appendix 4E and Analysts Presentation 18 Aug 2010 8:32AM $31.900 $190.440 risen by 496.99%
$91,389 Response to an ASX Query 23 Apr 2010 2:16PM $32.500 $190.440 risen by 485.97%
$91,389 Half Yearly Report and Accounts 17 Feb 2010 8:31AM $33.900 $190.440 risen by 461.77%
$91,389 Changes relating to buy-back - Appendix 3D 20 Oct 2009 10:39AM $31.970 $190.440 risen by 495.68%
$91,389 Chairman`s and MD`s Address to Shareholders 14 Oct 2009 10:09AM $32.000 $190.440 risen by 495.13%
$91,389 Full Year Results, Appendix 4E and Analysts Presentation 19 Aug 2009 8:39AM $33.100 $190.440 risen by 475.35%
$91,389 Accounting Treatment - Conversion of US $1.5B to AUD 22 Jun 2009 9:38AM $31.620 $190.440 risen by 502.28%
$91,389 CSL and Talecris agree to terminate Merger Agreement 9 Jun 2009 8:32AM $30.490 $190.440 risen by 524.60%
$91,389 CSL announces on-market share buyback 9 Jun 2009 8:32AM $30.490 $190.440 risen by 524.60%
$91,389 Announcement of buy-back - Appendix 3C 9 Jun 2009 8:32AM $30.490 $190.440 risen by 524.60%
$91,389 CSL Receives Order from U.S,. Government for H1N1 Vaccine 29 May 2009 8:27AM $29.200 $190.440 risen by 552.19%
$91,389 Confirms commitment to Talecris acquisition 28 May 2009 9:37AM $29.030 $190.440 risen by 556.01%
$91,389 Proposed Acquisition of Talecris 7 May 2009 10:38AM $31.910 $190.440 risen by 496.80%
$91,389 Half Yearly Report and Accounts 18 Feb 2009 8:27AM $36.830 $190.440 risen by 417.08%
$91,389 CSL receives FTC request on proposed merger with Talecris 13 Oct 2008 9:34AM $38.190 $190.440 risen by 398.66%
$91,389 Completes institutional equity raising 14 Aug 2008 2:01PM $37.650 $190.440 risen by 405.82%
$91,389 Preliminary Final Report Accounts and Media Release 13 Aug 2008 9:14AM $36.900 $190.440 risen by 416.10%
$91,389 CSL announces agreement to acquire Talecris 13 Aug 2008 9:14AM n/a $190.440 n/a
$91,389 Trading Halt 13 Aug 2008 8:43AM n/a $190.440 n/a
$91,389 CSL Half Yearly Report and Half Year Accounts 20 Feb 2008 8:54AM $37.200 $190.440 risen by 411.94%
$91,389 Unsolicited share offers 14 Feb 2008 3:44PM $32.050 $190.440 risen by 494.20%
$91,389 Current ASX Code 19 Oct 2007 4:34PM $33.900 $190.440 risen by 461.77%

1126 - 1150 of 1192 results

Page 46 of 48

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.